Epigral Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 6, 2025, 5:12 pm

Competitors of Epigral Ltd

All Competitor Stocks of Epigral Ltd

Quarterly Result

Last Updated: August 19, 2025, 3:47 pm

Below is a detailed analysis of the quarterly data for Epigral Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 607.00 Cr.. The value appears to be declining and may need further review. It has decreased from 628.00 Cr. (Mar 2025) to 607.00 Cr., marking a decrease of 21.00 Cr..
• For Expenses, as of Jun 2025, the value is 443.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 454.00 Cr. (Mar 2025) to 443.00 Cr., marking a decrease of 11.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 163.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Mar 2025) to 163.00 Cr., marking a decrease of 10.00 Cr..
• For OPM %, as of Jun 2025, the value is 27.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Mar 2025) to 27.00%, marking a decrease of 1.00%.
• For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 11.00 Cr..
• For Depreciation, as of Jun 2025, the value is 42.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Mar 2025) to 42.00 Cr., marking an increase of 8.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 107.00 Cr.. The value appears to be declining and may need further review. It has decreased from 131.00 Cr. (Mar 2025) to 107.00 Cr., marking a decrease of 24.00 Cr..
• For Tax %, as of Jun 2025, the value is -50.00%. The value appears to be improving (decreasing) as expected. It has decreased from 34.00% (Mar 2025) to -50.00%, marking a decrease of 84.00%.
• For Net Profit, as of Jun 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 87.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 73.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 37.18. The value appears strong and on an upward trend. It has increased from 20.08 (Mar 2025) to 37.18, marking an increase of 17.10.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:24 am

Growth

Last Updated: September 5, 2025, 3:26 pm

Balance Sheet

Last Updated: July 25, 2025, 1:21 pm

Below is a detailed analysis of the balance sheet data for Epigral Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 43.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2024) to 43.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,860.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,213.00 Cr. (Mar 2024) to 1,860.00 Cr., marking an increase of 647.00 Cr..
• For Borrowings, as of Mar 2025, the value is 593.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 964.00 Cr. (Mar 2024) to 593.00 Cr., marking a decrease of 371.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 655.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 576.00 Cr. (Mar 2024) to 655.00 Cr., marking an increase of 79.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 3,151.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,794.00 Cr. (Mar 2024) to 3,151.00 Cr., marking an increase of 357.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,238.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,767.00 Cr. (Mar 2024) to 2,238.00 Cr., marking an increase of 471.00 Cr..
• For CWIP, as of Mar 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 483.00 Cr. (Mar 2024) to 64.00 Cr., marking a decrease of 419.00 Cr..
• For Investments, as of Mar 2025, the value is 97.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2024) to 97.00 Cr., marking an increase of 76.00 Cr..
• For Other Assets, as of Mar 2025, the value is 752.00 Cr.. The value appears strong and on an upward trend. It has increased from 524.00 Cr. (Mar 2024) to 752.00 Cr., marking an increase of 228.00 Cr..
• For Total Assets, as of Mar 2025, the value is 3,151.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,794.00 Cr. (Mar 2024) to 3,151.00 Cr., marking an increase of 357.00 Cr..

Notably, the Reserves (1,860.00 Cr.) exceed the Borrowings (593.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Epigral Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
• For Diluted EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
• For Cash EPS (Rs.), as of Mar 25, the value is 113.41. This value is within the healthy range. It has increased from 76.87 (Mar 24) to 113.41, marking an increase of 36.54.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 591.13. It has increased from 464.30 (Mar 24) to 591.13, marking an increase of 126.83.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 168.27. This value is within the healthy range. It has increased from 117.39 (Mar 24) to 168.27, marking an increase of 50.88.
• For PBIT / Share (Rs.), as of Mar 25, the value is 137.54. This value is within the healthy range. It has increased from 87.66 (Mar 24) to 137.54, marking an increase of 49.88.
• For PBT / Share (Rs.), as of Mar 25, the value is 125.20. This value is within the healthy range. It has increased from 69.97 (Mar 24) to 125.20, marking an increase of 55.23.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 82.68. This value is within the healthy range. It has increased from 47.13 (Mar 24) to 82.68, marking an increase of 35.55.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 82.91. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 82.91, marking an increase of 35.77.
• For PBDIT Margin (%), as of Mar 25, the value is 28.46. This value is within the healthy range. It has increased from 25.28 (Mar 24) to 28.46, marking an increase of 3.18.
• For PBIT Margin (%), as of Mar 25, the value is 23.26. This value exceeds the healthy maximum of 20. It has increased from 18.87 (Mar 24) to 23.26, marking an increase of 4.39.
• For PBT Margin (%), as of Mar 25, the value is 21.17. This value is within the healthy range. It has increased from 15.06 (Mar 24) to 21.17, marking an increase of 6.11.
• For Net Profit Margin (%), as of Mar 25, the value is 13.98. This value exceeds the healthy maximum of 10. It has increased from 10.15 (Mar 24) to 13.98, marking an increase of 3.83.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.02. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 14.02, marking an increase of 3.87.
• For Return on Networth / Equity (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has increased from 15.61 (Mar 24) to 18.78, marking an increase of 3.17.
• For Return on Capital Employeed (%), as of Mar 25, the value is 22.30. This value is within the healthy range. It has increased from 18.07 (Mar 24) to 22.30, marking an increase of 4.23.
• For Return On Assets (%), as of Mar 25, the value is 11.34. This value is within the healthy range. It has increased from 7.00 (Mar 24) to 11.34, marking an increase of 4.34.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.23, marking a decrease of 0.16.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.72 (Mar 24) to 0.30, marking a decrease of 0.42.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has increased from 0.73 (Mar 24) to 0.85, marking an increase of 0.12.
• For Current Ratio (X), as of Mar 25, the value is 1.57. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 1.57, marking an increase of 0.93.
• For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has increased from 0.30 (Mar 24) to 0.78, marking an increase of 0.48.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.06. This value is within the healthy range. It has decreased from 4.51 (Mar 24) to 4.06, marking a decrease of 0.45.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 5.30 (Mar 24) to 8.82, marking an increase of 3.52.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 20. It has increased from 3.25 (Mar 24) to 6.43, marking an increase of 3.18.
• For Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 94.70 (Mar 24) to 91.18, marking a decrease of 3.52.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.57. This value exceeds the healthy maximum of 70. It has decreased from 96.75 (Mar 24) to 93.57, marking a decrease of 3.18.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 13.63. This value is within the healthy range. It has increased from 6.64 (Mar 24) to 13.63, marking an increase of 6.99.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.70. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 7.70, marking an increase of 4.04.
• For Enterprise Value (Cr.), as of Mar 25, the value is 8,753.81. It has increased from 5,509.59 (Mar 24) to 8,753.81, marking an increase of 3,244.22.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 2.86 (Mar 24) to 3.43, marking an increase of 0.57.
• For EV / EBITDA (X), as of Mar 25, the value is 12.06. This value is within the healthy range. It has increased from 11.30 (Mar 24) to 12.06, marking an increase of 0.76.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
• For Retention Ratios (%), as of Mar 25, the value is 91.17. This value exceeds the healthy maximum of 70. It has decreased from 94.69 (Mar 24) to 91.17, marking a decrease of 3.52.
• For Price / BV (X), as of Mar 25, the value is 4.30. This value exceeds the healthy maximum of 3. It has increased from 3.63 (Mar 24) to 4.30, marking an increase of 0.67.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness